AbbVie Inc (ABBV)
ABBV (NYSE:Drugs)
$43.54
+0.53
+1.23%
Today's Range: 42.63 - 43.56 |
ABBV Avg Daily Volume: 6,258,400
| Last Update: 06/18/13 - 4:02 PM EDT |
| Volume: 3,556,123 |
| YTD Performance: 25.91%
|
| Open: $42.97 |
| Previous Close: $43.01 |
| 52 Week Range: $32.51 -
$48.00 |
| Oustanding Shares: 1,583,729,114 |
| Market Cap: 68,432,935,016 |
6-Month Chart
TheStreet Ratings Grade for ABBV
| Buy |
Hold
|
Sell
|
| A+ |
A |
A- |
B+ |
B |
B- |
C+ |
C |
C- |
D+ |
D |
D- |
E+ |
E |
E- |
F |
Analysts Ratings
| Historical Rec |
Current |
1 Mo. Ago |
2 Mo. Ago |
3 Mo. Ago |
| Strong Buy |
4 |
3 |
4 |
4 |
| Moderate Buy |
1 |
1 |
0 |
0 |
| Hold |
6 |
6 |
7 |
7 |
| Moderate Sell |
0 |
0 |
0 |
0 |
| Strong Sell |
0 |
0 |
0 |
0 |
| Mean Rec. |
2.14 |
2.25 |
2.27 |
2.27 |
| Latest Dividend: |
0.40 |
| Latest Dividend Yield: |
3.70% |
| Dividend Ex-Date: |
04/11/13 |
| Price Earnings Ratio: |
12.75 |
|
| Price Earnings Comparisons: |
| ABBV |
Sector Avg. |
S&P 500 |
| 12.75 |
10.90 |
17.70 |
| Price Performance History (%Change): |
| 3 Mo |
1 Yr |
3 Y |
|
11.71%
|
0.00%
|
0.00%
|
|
| GROWTH |
12 Mo |
3 Yr |
CAGR |
| Revenue |
5.40 |
0.00 |
0.00 |
| Net Income |
53.70 |
0.00 |
0.00 |
| EPS |
0.00 |
0.00 |
0.00 |
| Earnings for ABBV: |
| EBITDA |
6.97B |
| Revenue |
18.38B |
|
Average Earnings Estimates
;Qtr (09/13);FY (12/13);FY (12/14)&HEADING_LIST1=Qtr (06/12);Qtr (09/12);FY (12/12);FY (12/13)) |
|
| Average Estimate |
$0.79 |
$0.77 |
$3.13 |
$3.23 |
| Number of Analysts |
6 |
5 |
9 |
7 |
| High Estimate |
$0.80 |
$0.78 |
$3.17 |
$3.32 |
| Low Estimate |
$0.78 |
$0.76 |
$3.10 |
$3.15 |
| Prior Year |
$0.80 |
$1.01 |
$3.35 |
$3.13 |
| Growth Rate (Year over Year) |
-1.04% |
-23.56% |
-6.60% |
3.14% |
| May 29, 2013 | 3:00 PM EDT
The billionaire's hedge fund bought heavily into this theme in the first quarter.
| May 15, 2013 | 1:00 PM EDT
Today's investment environment has more moving parts than ever.
| May 10, 2013 | 12:00 PM EDT
The objective of investing is to offset future liabilities and manage risk.
| Apr 24, 2013 | 1:16 PM EDT
It’s the only thing that explains today’s action.
Apr 22, 2013 | 7:41 AM EDT
ABBV was upgraded from Equal-weight to Overweight, Morgan Stanley said. $49 price target. Expect higher Humira sales and the company ha...
| Apr 11, 2013 | 10:24 AM EDT
Plenty of leadership remains in the health care sector and there’s reason to see further potential.
| Apr 10, 2013 | 1:30 PM EDT
Pickings are slim this month but get prepared for the deluge coming in May.
| Apr 08, 2013 | 2:30 PM EDT
These recent IPOs offer noteworthy returns.
Apr 01, 2013 | 8:19 AM EDT
ABBV was downgraded from Outperform to Market Perform, BMO Capital said. Valuation call, based on a $42 price target.
Feb 07, 2013 | 8:05 AM EST
ABBV was initiated with a Neutral rating, Credit Suisse said. $37 price target. Cross currents imply minimal stock movement from curren...
